Modifier Gene Therapy

Mechanism

Related News

Ocugen to Report Q4 and Full Year 2025 Results on March 4, 2026

Mar 04, 2026

Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.

Ocugen Completes Enrollment in Phase 3 Gene Therapy Trial for Retinitis Pigmentosa

Mar 03, 2026

Ocugen has completed enrollment of 140 patients in its Phase 3 liMeliGhT trial for OCU400, a gene therapy for retinitis pigmentosa. Topline data expected in Q1 2027 could support potential approval later that year.